Celldex Therapeutics, Inc. may offer common stock, preferred stock, warrants, depositary shares and units from time to time, with specific offering terms and net proceeds to be specified in prospectus supplements.
CLDX · Celldex Therapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Celldex Therapeutics, Inc. reported that two Phase 3 barzolvolimab studies in CSU met primary and all key secondary endpoints, with 1,939 patients enrolled; it plans to submit a BLA to the FDA in 2027.
Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 met primary and key secondary endpoints, supporting barzolvolimab in CSU, with a BLA submission planned for 2027. Celldex Therapeutics reported $650.3 million in cash, cash equivalents and marketable securities, funding planned operations through 2028.
Celldex reported that barzolvolimab met primary and all key secondary endpoints at 12 weeks in two Phase 3 chronic spontaneous urticaria trials, with favorable safety through 24 weeks and a planned FDA BLA submission in 2027.